LONDON and PHILADELPHIA – July 9, 2025 – Avacta (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, confirms that it has received an accelerated payment notice from the convertible bond holder in respect of the January 2026 quarterly deferred convertible bond repayment, as referenced most recently in the financing announced on 5 June 2026, which the Company has elected to settle in cash. Accordingly, the Company has settled the accelerated quarterly amortization payment of £3.67 million representing principal of £2.4 million together with the associated interest and fees paylable in the deferrment.
After settlement of this quarterly repayment, the principal remaining under the convertible bond will be reduced to £16.8 million.